Improvement of Diffusion Tensor Imaging (DTI) Parameters with Decoppering Treatment in Wilson’s Disease

  • A. Lawrence
  • J. Saini
  • S. SinhaEmail author
  • S. Rao
  • M. Naggappa
  • P. S. Bindu
  • A. B. Taly
Research Report
Part of the JIMD Reports book series (JIMD, volume 25)


Objective: This study was undertaken to analyse serially the effects of decoppering therapy on the clinical features, disability and MRI brain including DTI metrics in patients with Wilson’s disease.

Methods and Results: Thirty-five patients with clinically and serologically confirmed neuropsychiatric form of Wilson’s disease (WD) on decoppering therapy were followed for a minimum duration of 1 year with serial assessment of their clinical features, disability status and serial MR imaging of the brain including DTI. The cohort included 18 treatment-naïve patients and 17 patients already on decoppering therapy (M/F = 2.18:1). The mean age at which they underwent baseline assessment for this study was 18.6 ± 7.6 years, and follow-up assessment was done after a mean duration of 23.5 ± 8.8 months (range, 12 to 45 months). Along with the overall clinical improvement noted at follow-up, the disability assessed using Chu staging and MSEADL showed significant reduction in the number of patients with severe disability and the mean NSS reducing from 9.74 to 6.37 (p = 0.002). The mean MRI scores showed significantly reduced disease burden from a baseline score of 5.9 (±4.2) to 4.9 (±4.7) in follow-up scans (p < 0.05). Voxel-wise comparison of serial DTI metrics on TBSS (tract-based spatial statistics) analysis showed that the entire cohort had significant (p < 0.05) improvement in all the four parameters (MD, FA, DA and RD) indicated by a decrease in MD, DA and RD values and increase in FA values. Comparison of whole-brain white matter DTI measures between pre- and posttreatment did not show any significant difference (p < 0.05).

Conclusion: Patients with Wilson’s disease on decoppering therapy showed clinical improvement accompanied with improvement in DTI metrics. Quantitative DTI metrics may be used as surrogate markers of clinical status following initiation of medical therapy in Wilson’s disease.


DTI MRI Wilson’s disease 


  1. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML (2007) Wilson’s disease. Lancet 369:397–408CrossRefPubMedGoogle Scholar
  2. Chu NS (1986) Sensory evoked potentials in Wilson’s disease. Brain 109:491–507CrossRefPubMedGoogle Scholar
  3. Favrole P, Chabriat H, Guichard JP, Woimant F (2006) Clinical correlates of cerebral water diffusion in Wilson disease. Neurology 66:384–389CrossRefPubMedGoogle Scholar
  4. Jadav R, Saini J, Sinha S, Bagepally B, Rao S, Taly AB (2013) Diffusion Tensor Imaging (DTI) and its clinical correlates in drug naïve Wilson’s disease. Metabolic Brain Dis 28:455–462CrossRefGoogle Scholar
  5. Kim TJ, Kim IO, Kim WS et al (2006) MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation. AJNR Am J Neuroradiol 27:1373–1378PubMedGoogle Scholar
  6. King AD, Walshe JM, Kendall BE, Chinn RJ, Paley MN, Wilkinson ID, Halligan S, Hall-Craggs MA (1996) Cranial MR changes in Wilson’s disease. Am J Roentgenol 167(6):1579–1584CrossRefGoogle Scholar
  7. Larnaout A, Ammar N, Mourad Z, Naji S, Hentati F (2008) Wilson's disease: appreciable improvement of sub-cortical white matter abnormalities after copper chelating treatment: five years follow-up. Neuropediatrics 39:176–178CrossRefPubMedGoogle Scholar
  8. Le Bihan D, Mangin JF, Poupon C et al (2001) Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 13:534–546CrossRefPubMedGoogle Scholar
  9. Magalhaes AC, Caramelli P, Menezes JR et al (1994) Wilson’s disease: MRI with clinical correlation. Neuroradiology 36:97–100CrossRefPubMedGoogle Scholar
  10. Meenakshi-Sundaram S, Taly AB, Kamath V, Arunodaya GR, Rao S, Swamy HS (2002) Autonomic dysfunction in Wilson’s disease – a clinical and electrophysiological study. Clin Auton Res 12:185–189CrossRefPubMedGoogle Scholar
  11. Prayer L, Wimberger D, Kramer J, Grimm G, Oder W, Imhof H (1990) Cranial MRI in Wilson’s disease. Neuroradiology 32:211–214CrossRefPubMedGoogle Scholar
  12. Schwab R, England A (1960) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham F, Donaldson I (eds) Theme symposium on Parkinson’s disease, 1 edn. E&S Livingston, LondonGoogle Scholar
  13. Sener RN (2003a) Diffusion MR imaging changes associated with Wilson disease. AJNR Am J Neuroradiol 24:965–967PubMedGoogle Scholar
  14. Sener RN (2003b) Diffusion MRI findings in Wilson’s disease. Comput Med Imaging Graph 27:17–21CrossRefPubMedGoogle Scholar
  15. Sinha S, Taly AB, Ravishankar S et al (2006) Wilson's disease: cranial MRI observations and clinical correlation. Neuroradiology 48:613–621CrossRefPubMedGoogle Scholar
  16. Sinha S, Taly AB, Ravishankar S, Prashanth LK, Vasudev MK (2007a) Central pontine signal changes in Wilson’s disease: distinct MRI morphology and sequential changes with de-coppering therapy. J Neuroimaging 17:286–291CrossRefPubMedGoogle Scholar
  17. Sinha S, Taly AB, Prashanth LK, Ravishankar S, Arunodaya GR, Vasudev MK (2007b) Sequential MRI changes in Wilson's disease with de-coppering therapy: a study of 50 patients. Br J Radiol 80:744–749CrossRefPubMedGoogle Scholar
  18. Smith SM, Nichols TE (2009) Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 44:83–98CrossRefPubMedGoogle Scholar
  19. Smith SM, Jenkinson M, Johansen-Berg H et al (2006) Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data. Neuroimage 31:1487–1505CrossRefPubMedGoogle Scholar
  20. Starosta-Rubinstein S, Young AB, Kluin K et al (1987) Clinical assessment of 31 patients with Wilson’s disease. Correlations with structural changes on magnetic resonance imaging. Arch Neurol 44:365–370CrossRefPubMedGoogle Scholar
  21. Stejskal EO, Tanner JE (1965) Spin diffusion measurements: spin echoes in the presence of a time‐dependent field gradient. J Chem Phys 42:288–292CrossRefGoogle Scholar
  22. Tarnacka B, Szeszkowski W, Golebiowski M, Czlonkowska A (2008) MR spectroscopy in monitoring the treatment of Wilson’s disease patients. Mov Disord 23:1560–1566CrossRefPubMedGoogle Scholar
  23. van Wassenaer-van Hall HN, van den Heuvel AG, Algra A, Hoogenraad TU, Mali WP (1996) Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 198:531–536CrossRefPubMedGoogle Scholar
  24. Walshe JM (1962) Wilson’s disease. The presenting symptoms. Arch Dis Child 37:253–256CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • A. Lawrence
    • 1
  • J. Saini
    • 2
  • S. Sinha
    • 1
    Email author
  • S. Rao
    • 3
  • M. Naggappa
    • 1
  • P. S. Bindu
    • 1
  • A. B. Taly
    • 1
  1. 1.Department of NeurologyNIMHANSBengaluruIndia
  2. 2.Department of NIIRNIMHANSBengaluruIndia
  3. 3.Department of BiostatisticsNIMHANSBengaluruIndia

Personalised recommendations